AnGes

About

AnGes MG, Inc. is a biopharmaceutical company with a mission to provide patients, especially those suffering from disease for which no effective therapy has been available to date, with innovative drugs. AnGes focuses on development of gene medicine, a next-generation biopharmaceutical. AnGes MG, Inc. was founded in December 1999 on an innovative discovery by researchers at Osaka University. AnGes already went through the first stage of research and development and is now in the second stage of commercialization. “Naglazyme®,” a drug for the treatment of mucopolysaccharidosis VI, an intractable disease, has already been marketed in Japan and HGF Plasmid (gene therapy) for the treatment of critical limb ischemia, which is a serious impairment of blood circulation in the legs, is in the last stage of clinical development. Development of “NF-κB decoy oligonucleotide,” a nucleic acid medicine that suppresses various types of inflammation including atopic dermatitis, disc degeneration, and

Investment Focus

Sectors

healthtech biotech

Location

Tokyo, Japan